Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
132 hedge funds and large institutions have $209M invested in Antares Pharma, Inc. in 2019 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 39 increasing their positions, 34 reducing their positions, and 13 closing their positions.
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
16% more capital invested
Capital invested by funds: $181M → $209M (+$28.2M)
15% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 34
10% more funds holding
Funds holding: 120 → 132 (+12)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
22% less call options, than puts
Call options by funds: $1.77M | Put options by funds: $2.26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.26M |
| 2 |
CAM
Cortina Asset Management
Milwaukee,
Wisconsin
|
+$3.35M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.72M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$1.84M |
| 5 |
Renaissance Technologies
New York
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.01M |
| 2 |
BC
Broadfin Capital
New York
|
-$2.59M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$1.8M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.78M |
| 5 |
BlackRock
New York
|
-$1.05M |
ATRS Hedge Fund Activity: Q1 2019 in Review
132 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q1 2019, worth a combined $209M — up 16% from $181M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ATRS positions and 13 closed out — a net gain of 12 holders — while 39 added to existing stakes and 34 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $4.26M. The largest seller was Millennium Management, cutting an estimated $4.01M.
- 132 institutional investors held Antares Pharma, Inc. (ATRS) as of Q1 2019, up from 120 in Q4 2018.
- Funds reported $209M of Antares Pharma, Inc. stock for Q1 2019, up 16% quarter-over-quarter.
- 25 funds opened new Antares Pharma, Inc. positions in Q1 2019 and 13 closed out, a net change of +12 holders.
- The largest Antares Pharma, Inc. buyer in Q1 2019 was Morgan Stanley, an estimated $4.26M added.
- The largest Antares Pharma, Inc. seller in Q1 2019 was Millennium Management, an estimated $4.01M sold.
Based on aggregated 13F filings for Q1 2019.